title: Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes.
abstract: Primary plasma cell leukaemia (PPCL) is a rare form of plasma cell neoplasm. Treatments of PPCL have been most disappointing. A patient with PPCL received high-dose melphalan plus total body irradiation and autologous bone marrow transplantation (ABMT). By using third-complementarity-determining region (CDRIII)-specific probes, minimal residual disease (MRD) was detected in remission marrow, collected 1 month before ABMT. MRD was no longer detected by CDRIII-specific probes 6, 19 and 26 months after transplantation. The patient remained in complete remission up to 59 months after ABMT.
authors.affiliation: Department of Oncology, National Taiwan University Hospital, Taipei, R.O.C.
authors.forename: K H
authors.initials: KH
authors.lastname: Yeh
authors.forename: M T
authors.initials: MT
authors.lastname: Lin
authors.forename: J L
authors.initials: JL
authors.lastname: Tang
authors.forename: C H
authors.initials: CH
authors.lastname: Yang
authors.forename: W
authors.initials: W
authors.lastname: Tsay
authors.forename: Y C
authors.initials: YC
authors.lastname: Chen
mesh_terms: D000328:Adult; D001483:Base Sequence; D016026:Bone Marrow Transplantation; D015342:DNA Probes; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000628:therapy*; D008969:Molecular Sequence Data; D018365:Neoplasm, Residual / Q000175:diagnosis*; D014184:Transplantation, Homologous
chemical_list: D015342:DNA Probes